scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers.

TL;DR: This article systematically introduces the concepts and amelioration mechanisms of the nanomedical techniques for drug- and natural compound-loaded SLNs.
About: This article is published in Journal of Food and Drug Analysis.The article was published on 2017-04-01 and is currently open access. It has received 195 citations till now. The article focuses on the topics: Solid lipid nanoparticle.
Citations
More filters
Journal ArticleDOI
TL;DR: This review highlights the NLC with focus on the structure, the various fabrication techniques used and the characterization techniques which are critical in the development of a suitable and stable formulation.

293 citations

Journal ArticleDOI
TL;DR: Although incorporation of curcumin into nanocarriers can be a possible solution to overcome its inherent constraints, there are some rational concerns about their toxicological safety once they enter into the biological paths, so future investigations could focus on assessment of their biological fate during digestion and absorption within human body.
Abstract: Curcumin is the main polyphenol of the curcuminoid class of turmeric, a well-known spice belonging to the ginger family. In addition to its common applications like coloring and antioxidant agent as food additives, it has a broad range of favorable biological functions, such as anti-inflammatory, anti-microbial, anti-diabetic activities, and anti-cancer potentials against various cancers. However, curcumin suffers from some limitations including short shelf life due to its poor chemical stability, low bioavailability due to its poor absorption, low water solubility, rapid metabolism and rapid systemic elimination. Nanoencapsulaion has been addressed as an innovative and emerging technology for resolving these shortcomings. In this review, the different delivery systems used for loading of curcumin have been considered and explained including lipid-based, chemical polymer and biopolymer-based, nature-inspired, special equipment-based and surfactant-based techniques. Also, implications of nanoencapsulated curcumin in food, pharmaceutical and cosmetic uses are discussed. In this sense, the relevant recent studies in the past few years along with upcoming challenges have been covered. Although incorporation of curcumin into nanocarriers can be a possible solution to overcome its inherent constraints, there are some rational concerns about their toxicological safety once they enter into the biological paths. Therefore, future investigations could focus on assessment of their biological fate during digestion and absorption within human body.

190 citations


Cites background from "Recent advances in oral delivery of..."

  • ...Phospholipids (soy lecithin and egg lecithin), ionic surfactants (sodium lauryl sulfate, sodium cholate, trimethylammonium bromide and stearylamine), nonionic surfactants (Poloxamer, Span, Pluronic, Tween and Brij), polyvinyl alcohol (PVA) and PEG are the emulsifiers or surfactants commonly used to stabilize the interface between the aqueous medium and the SLN shell (Lin et al. 2017)....

    [...]

  • ...…sodium cholate, trimethylammonium bromide and stearylamine), nonionic surfactants (Poloxamer, Span, Pluronic, Tween and Brij), polyvinyl alcohol (PVA) and PEG are the emulsifiers or surfactants commonly used to stabilize the interface between the aqueous medium and the SLN shell (Lin et al. 2017)....

    [...]

Journal ArticleDOI
TL;DR: Focusing on cell delivery, SLNs can improve drug delivery to target cells by different mechanisms, such as passive mechanisms that take advantage of the tumor microenvironment, active mechanisms by surface modification of SLNs, and codelivery mechanisms.
Abstract: Drug delivery systems have opened new avenues to improve the therapeutic effects of already-efficient molecules. Particularly, Solid Lipid Nanoparticles (SLNs) have emerged as promising nanocarriers in cancer therapy. SLNs offer remarkable advantages such as low toxicity, high bioavailability of drugs, versatility of incorporation of hydrophilic and lipophilic drugs, and feasibility of large-scale production. Their molecular structure is crucial to obtain high quality SLN preparations and it is determined by the relationship between the composition and preparation method. Additionally, SLNs allow overcoming several physiological barriers that hinder drug delivery to tumors and are also able to escape multidrug resistance mechanisms, characteristic of cancer cells. Focusing on cell delivery, SLNs can improve drug delivery to target cells by different mechanisms, such as passive mechanisms that take advantage of the tumor microenvironment, active mechanisms by surface modification of SLNs, and codelivery mechanisms. SLNs can incorporate many different drugs and have proven to be effective in different types of tumors (i.e., breast, lung, colon, liver, and brain), corroborating their potential. Finally, it has to be taken into account that there are still some challenges to face in the application of SLNs in anticancer treatments but their possibilities seem to be high.

173 citations


Cites background from "Recent advances in oral delivery of..."

  • ...Focusing on oral administration, despite being considered one of the most proper routes for the administration of medicines, it is not currently an option used in chemotherapy due to the low bioavailability of drugs through this route [34]....

    [...]

Journal ArticleDOI
TL;DR: This review evaluates recent advances in the development of phytochemical oral delivery systems, including microemulsions, nanoemulsion, emulsion, solid lipid nanoparticles, liposomes, and biopolymer microgels.

167 citations

Journal ArticleDOI
TL;DR: The aim of this review is to provide recent updates on drug resistance mechanisms, newly developed/repurposed anti‐TB agents in pipeline and international recommendations to manage MDR‐TB, based on recent literature and WHO guidelines and aims to facilitate better understanding of drug resistance for effective TB therapy and clinical management.
Abstract: Tuberculosis (TB) along with acquired immune deficiency syndrome and malaria rank among the top three fatal infectious diseases which pose threat to global public health, especially in middle and low income countries. TB caused by Mycobacterium tuberculosis (Mtb) is an airborne infectious disease and one-third of the world's population gets infected with TB leading to nearly 1·6 million deaths annually. TB drugs are administered in different combinations of four first-line drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) which form the core of treatment regimens in the initial treatment phase of 6-9 months. Several reasons account for the failure of TB therapy such as (i) late diagnosis, (ii) lack of timely and proper administration of effective drugs, (iii) lower availability of less toxic, inexpensive and effective drugs, (iv) long treatment duration, (v) nonadherence to drug regimen and (vi) evolution of drug-resistant TB strains. Drug-resistant TB poses a significant challenge to TB therapy and control programs. In the background of worldwide emergence of 558 000 new TB cases with resistance to rifampicin in the year 2017 and of them, 82% becoming multidrug-resistant TB (MDR-TB), it is essential to continuously update the knowledge on the mechanisms and molecular basis for evolution of Mtb drug resistance. This narrative and traditional review summarizes the progress on the anti-tubercular agents, their mode of action and drug resistance mechanisms in Mtb. The aim of this review is to provide recent updates on drug resistance mechanisms, newly developed/repurposed anti-TB agents in pipeline and international recommendations to manage MDR-TB. It is based on recent literature and WHO guidelines and aims to facilitate better understanding of drug resistance for effective TB therapy and clinical management.

149 citations


Cites background from "Recent advances in oral delivery of..."

  • ...Drugs encapsulated in nanocarriers facilitate controlled release, higher bioavailability of drugs and minimum toxicity in comparison to the common drugs used in free form (Vyas et al. 2014; Nasiruddin et al. 2017; Lin et al. 2017)....

    [...]

References
More filters
Journal ArticleDOI
TL;DR: Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs.
Abstract: Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs. The pharmacokinetics (PK) and tissue distribution of the nanoparticles largely define their therapeutic effect and toxicity. Chemical and physical properties of the nanoparticles, including size, surface charge, and surface chemistry, are important factors that determine their PK and biodistribution. The intracellular fate of the nanoparticles after cellular internalization that affects the drug bioavailability is also discussed. Strategies for overcoming barriers for intracellular delivery and drug release are presented. Finally, future directions for improving the PK of nanoparticles and perspectives in the field are discussed.

1,380 citations


"Recent advances in oral delivery of..." refers background in this paper

  • ...The inclusion of paclitaxel into WGA-coated SLNs led to doubling of MRT in contrast to the control solution....

    [...]

  • ...With respect to pharmacokinetics, the drugs in nanocarriers generally revealed prolonged circulation time, increased half-life, reduced clearance, and increased mean residence time (MRT) [5]....

    [...]

  • ...In the in vivo pharmacokinetics, theMRTwas found to be 13.9 hours and 9.6 hours for polymer-coated SLNs and aqueous suspension, respectively....

    [...]

Journal ArticleDOI
TL;DR: The protective barrier properties of mucus secretions, how mucus affects the fate of orally administered nanoparticles, and recent developments in nanoparticles engineered to penetrate the mucus barrier are addressed.

1,205 citations


"Recent advances in oral delivery of..." refers background in this paper

  • ...epithelial cell monolayer in the GI membrane also contributes to poor permeability for numerous drugs [2]....

    [...]

Journal ArticleDOI
TL;DR: Critical determinants that can affect the generation of ROS include size, shape, particle surface, surface positive charges, surface-containing groups, particle dissolution, metal ion release from nanometals and nanometal oxides, UV light activation, aggregation, mode of interaction with cells, inflammation, and pH of the medium.

995 citations


"Recent advances in oral delivery of..." refers background in this paper

  • ...[20] Fu PP, Xia Q, Hwang HM, Ray PC, Yu H....

    [...]

  • ...The safety of oral nanoformulations is a serious concern for their application [19,20]....

    [...]

Journal ArticleDOI
TL;DR: How curcumin should be delivered in vivo, how bioavailable is it, how wellCurcumin is absorbed and how it is metabolized, is the focus of this review.
Abstract: Curcumin (diferuloylmethane) is a yellow pigment present in the spice turmeric (Curcuma longa) that has been associated with antioxidant, anti-inflammatory, anticancer, antiviral, and antibacterial activities as indicated by over 6,000 citations. In addition, over one hundred clinical studies have been carried out with curcumin. One of the major problems with curcumin is perceived to be the bioavailability. How curcumin should be delivered in vivo, how bioavailable is it, how well curcumin is absorbed and how it is metabolized, is the focus of this review. Various formulations of curcumin that are currently available are also discussed.

792 citations


"Recent advances in oral delivery of..." refers background in this paper

  • ...The oral bioavailability of curcumin is less than 1% because this compound has poor aqueous solubility and rapid metabolism [83]....

    [...]

Journal ArticleDOI
TL;DR: Solid lipid particulate systems such as solid lipid nanoparticles (SLN), lipid microparticles (LM) and lipospheres) seem to fulfil the requirements for an optimum particulate carrier system for therapeutic peptides, proteins and antigens.

742 citations


"Recent advances in oral delivery of..." refers background in this paper

  • ...Researchers focus considerable attention on SLNs as the carriers to protect peptides and proteins known for their sensitivity to various environmental factors such as pH, temperature, and ionic strength [115]....

    [...]